Journal
NEPHROLOGY
Volume 28, Issue 2, Pages 97-108Publisher
WILEY
DOI: 10.1111/nep.14130
Keywords
chronic kidney disease; endothelin; fluid retention; kidney failure; proteinuria
Categories
Ask authors/readers for more resources
The burden of chronic kidney disease is increasing globally due to the rise in diabetes and hypertension. Current treatments, such as renin angiotensin system inhibitors, are only partially effective, highlighting the need for additional therapies to prevent kidney failure. Endothelin receptor antagonism shows promise in protecting the kidneys from further damage and may be used in both diabetic and non-diabetic kidney disease.
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global prevalence of diabetes mellitus and hypertension. While renin angiotensin system inhibitors and sodium-glucose cotransporter two inhibitors are the management cornerstone for reducing kidney and cardiovascular complications in patients with diabetic and non-diabetic kidney disease (DKD), they are partially effective and further treatments are needed to prevent the progression to kidney failure. Endothelin receptor antagonism represent a potential additional therapeutic option due to its beneficial effect on pathophysiological processes involved in progressive kidney disease including proteinuria, which are independently associated with progression of kidney disease. This review discusses the biological mechanisms of endothelin receptor antagonists (ERA) in kidney protection, the efficacy and safety of ERA in randomised controlled trials reporting on kidney outcomes, and its potential future use in both diabetic and non-DKDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available